AI assistant
PFIZER INC — Director's Dealing 2024
Aug 6, 2024
29831_dirs_2024-08-05_8a2bccaa-9475-4546-9e48-0b2e39867393.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Cerevel Therapeutics Holdings, Inc. (CERE)
CIK: 0001805387
Period of Report: 2024-08-01
Reporting Person: PFIZER INC (Former 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-08-01 | Common Stock | U | 27349211 | $45 | Disposed | 0 | Direct |
Footnotes
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("AbbVie"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of AbbVie upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.